PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 3, 2005, Pages 616-619

  Ulrich, Cornelia M ^a,b   Whitton, John ^a   Yu, Joon Ho ^a,b   Sibert, Justin ^a   Sparks, Rachel ^a   Potter, John D ^a,b   Bigler, Jeannette ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Department of Epidemiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ADULT; AGED; ARTICLE; BINDING SITE; BODY MASS; CANCER INHIBITION; CANCER RISK; CASE CONTROL STUDY; COLON CANCER; COLORECTAL ADENOMA; CONTROLLED STUDY; FEMALE; GENE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MITOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN SYNTHESIS; PTGS2 GENE; RISK ASSESSMENT; RISK REDUCTION;

ADENOMA; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; INFLAMMATION; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ODDS RATIO; PEROXIDASES; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS;

EID: 16844364790     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0510     Document Type: Article

References (56)

1. Gilroy DW, Saunders MA, Sansores-Garcia L, Matijevic-Aleksic N, Wu KK. Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts. FASEB J 2001;15:288-90.
2. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-6.
3. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992;267:7991-4.
4. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7.
5. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A 1992;89:4888-92.
6. Kirschenbaum A, Liotta DR, Yao S, et al. Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts. J Clin Endocrinol Metab 2000;85:3436-41.
7. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1ββ- mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-5.
8. Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson PJ, Ericsson-Dahlstrand A. Inflammatory response: pathway across the blood-brain barrier. Nature 2001;410:430-1.
9. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 1994;14:1021-31.
10. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19:723-9.
11. Shaftel SS, Olschowka JA, Hurley SD, Moore AH, O'Banion MK. COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Research. Molecular Brain Research 2003;119:213-5.
12. Kis B, Snipes JA, Isse T, Nagy K, Busija DW. Putative cyclooxygenase-3 expression in rat brain cells. Journal of Cerebral Blood Flow & Metabolism 2003;23:1287-92.
13. Warner TD, Vojnovic I, Giuliano F, Jiminez R, Bishop-Bailey D, Mitchell JA. Cyclooxygenases-1, 2 and 3 and the production of prostaglandin 12: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. J Pharmacol Exp Ther 2004;May 17 (Epub ahead of print).
14. Dinchuk JE, Liu RQ, Trzaskos JM. COX-3: in the wrong frame in mind, [comment]. Immunol Lett 2003;86:121.
15. Eberhart CE, Coffey RJ, Radhika A, Giardiello EM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
16. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proceedings of the National Academy of Sciences of the United States of America 1996;93:4816-20.
17. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000;156:545-53.
18. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Ape δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
19. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4705-8.
20. Watanabe K, Kawamori T, Nakatsugi S, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999;59:5093-6.
21. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E([2]) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002;62:403-8.
22. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 2001;299:468-76.
23. UW-Variation Discovery Resource. http://pga.gs.washington.edu/.
24. Lin HJ, Lakkides KM, Keku TO, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002;11:1305-15.
25. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. [comment]. Arteriosclerosis Thrombosis and Vascular Biology 2002;22:1631-6.
26. Cipollone F, Toniato E, Martinotti S, et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004;291:2221-8.
27. Sheng H, Shao J, Hooton EB, Tsujii M, DuBois RN, Beauchamp RD. Cyclooxygenase-2 induction and transforming growth factor β growth inhibition in rat intestinal epithelial cells. Cell Growth Differ 1997;8:463-70.
28. Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 1996;5:779-84.
29. O'Brien M, Winawer SJ, Zauber AG, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990;98:371-9.
30. Ulrich CM, Bigler J, Sparks R, et al. Polymorphisms in PTGS1(= COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004;13: 889-93.
31. Sparks R, Bigler J, Sibert JG, Potter JD, Yasui Y, Ulrich CM. TGF(β)1 polymorphism (L10P) and risk of colorectal adenomatous and hyperplastic polyps. Int J Epidemiol 2004;33:955-61.
32. Morimoto LM, Newcomb PA, Ulrich CM, Bostick RM, Lais CJ, Potter JD. Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev 2002;11:1012-8.
33. Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev 1999;8:659-68.
34. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001;61:3566-9.
35. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29 -> C polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000;101: 2783-7.
36. Yamada Y, Miyauchi A, Takagi Y, Tanaka M, Mizuno M, Harada A. Association of the C-509 -> T polymorphism, alone of in combination with the T869 -> C polymorphism, of the transforming growth factor-β1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. J Mol Med 2001;79:149-56.
37. Suthanthiran M, Li B, Song JO, et al. Transforming growth factor-β 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 2000;97:3479-84.
38. Wiesner GL, Platzer P, Buxbaum S, et al. Testing for colon neoplasia susceptibility variants at the human COX2 locus. J Natl Cancer Inst 2001;93:635-9.
39. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004;25:229-35.
40. Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese health study. Br J Cancer 2004;90:1760-4.
41. Cox DG, Pontes C, Guino E, et al. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 2004;91:339-43.
42. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
43. Wynter CV, Walsh MD, Higuchi T, Leggett BA, Young J, Jass JR. Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut 2004;53:573-80.
44. Jass JR, Biden KG, Cummings MC, et al. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J Clin Pathol 1999;52:455-60.
45. Jass JR. Hyperplastic polyps and colorectal cancer: is there a link? Clin Gastroenterol Hepatol 2004;2:1-8.
46. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
47. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. B J Cancer 2004;90:93-9.
48. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Nonsteroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003;95:1784-91.
49. Holick CN, Michaud DS, Leitzmann MF, Willett WC, Giovannucci E. Aspirin use and lung cancer in men. British Journal of Cancer 2003;89:1705-8.
50. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-101.
51. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. Jama 2004;291:2433-40.
52. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. Jama 2004;291:585-90.
53. Williams A, Hennekens CH. The role of aspirin in cardiovascular diseases: forgotten benefits? Expert Opin Pharmacother 2004;5:109-15.
54. Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. Am J Manag Care 2002;8:S691-700.
55. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Eng J Med 1995;332: 1758-66.
56. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.